Fireside Chat, Interview
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
- Eli Lilly forecasts an 80% revenue growth rate for its GLP-1 class in the current quarter while expecting sales for Manjaro and other products to decline to zero upon patent exclusivity loss in the 2030s.
- The company plans to introduce a pill format for GLP-1 drugs next year and anticipates a new mental health-targeting GLP-1 variant becoming available in three to four years, pending successful clinical studies.
- Manufacturing expansion plans include announcing four new plants within the next six months to join six existing facilities, a move projected to create 20,000 construction jobs and 5,000 to 6,000 permanent manufacturing roles.
- Eli Lilly aims to reduce GLP-1 category prices through "single digit deflation," targeting 5% annually or potentially 10%, with specific out-of-pocket costs already lowered from $1,000 to $4.99 and expected to decrease further with oral medicines.
- Research and development spending is projected at $14.2 billion this year, representing 25% of sales, supported by a workforce of 4,200 PhD scientists and an acquisition strategy executing a deal approximately every two weeks.
- The company intends to leverage domestic manufacturing scale in China to combat counterfeit drugs, a strategy deemed difficult for competitors to replicate unless a Chinese state-owned enterprise enters the market.
- Future clinical development includes studies for bipolar disorder and major depressive disorder using GLP-1 variants focused on brain activity, alongside research into smoking cessation and addiction to gambling or online shopping via hedonic pathways.
- Eli Lilly expects to become a net exporter of its drugs at scale by investing in organic R&D and supply chain expansion, countering the current biotech sector downturn characterized by a decline in new checks from $20 billion to $5.5 billion annually.
- Market expectations indicate that competitors are using AI to create patent-avoiding derivatives, while First-to-File patent laws necessitate immediate filing to secure IP rights, and the biotech sector faces a "dumpster fire" of liquidity with half of public biotech trading at or below cash.
- The company projects that a "next big surprise category" will be brain diseases, which account for 40% of global suffering, and anticipates that low-dose GLP-1 usage in individuals over 60 may produce pleiotropic effects that extend longevity.
- Strategic plans involve balancing the moral imperative to lower prices against the need to fund future R&D, warning that prices reduced to $100 levels could extinguish incentives for future innovation.
- Eli Lilly anticipates Novo Nordisk will release dementia risk data in a few months, which the CEO expects likely will not be positive but may show directional trends, while also predicting a shift toward drugs targeting pre-disease states like pre-diabetes.
- The organization expects the biotech sector to recover from its current state, noting that AI and large language models have become substantially better and are viewed as significant assets for consumer research and healthcare information.
- Industry analysis suggests that the gray market for drugs stems from poor insurance coverage and high costs rather than a lack of US system incentives, while the mainstream media faces a prisoner's dilemma regarding drug advertising revenue.
- Future policy and research frameworks are expected to scrutinize the NIH budget of over $40 billion for VC-like efficiency and back-scratching, with a recommendation to fund ideas the market cannot solve independently rather than relying exclusively on university leads.
- The company believes the historical focus on anti-fat high-carb diets for 30 years is debunked and advocates for food system reform to make quality food cheaper, while also navigating potential regulatory shifts related to the "maha movement."